LifeMD (LFMD): Law Firm Investigates Health-Data Sharing Allegations
LifeMD, Inc., the telehealth company whose common stock trades on Nasdaq under LFMD, is the subject of a data-privacy investigation notice published by Open Class Actions.
According to the LifeMD data-privacy investigation page, a law firm is investigating whether prospective patients' health-intake answers on LifeMD's website were shared with third parties without consent. The page was published September 9 and updated September 10, 2026.
These are allegations under investigation. TickerPosts has not independently established that the alleged sharing occurred, and the notice is not a court finding that LifeMD violated the law.
What the investigation notice says
The page describes concerns about the possible sharing of sensitive intake information with third-party advertising networks. It seeks case-review submissions from people who were in California when they used the relevant LifeMD questionnaire on or before June 14, 2026.
The listed criteria include answering at least one intake question, not accepting the stated terms and consents, not creating an account or making a purchase, and not already having a lawyer for the claim. The source page provides the complete criteria and qualifications; this article does not determine anyone's eligibility.
The notice describes a private law-firm investigation. It does not identify a government agency as conducting this investigation. It also states that there is no settlement claim form for this investigation and that submitting the questionnaire does not file a lawsuit.
What this means for the LFMD news record
The cited notice concerns prospective patients' privacy allegations. It does not describe a securities claim for people who purchased LFMD shares. Stock ownership alone is not among its listed case-review criteria.
The notice does not quantify potential damages, a settlement obligation, or an effect on LifeMD's earnings. It therefore does not provide a basis for assigning a dollar value to financial exposure. This report also does not attribute a movement in LFMD's stock price to the notice.
No response from LifeMD to this specific investigation is included in the cited notice. That absence should not be read as an admission, a denial, or evidence that the company has not responded elsewhere.
Separately, what LifeMD reported about its business
In its August 5 second-quarter earnings release, LifeMD reported revenue of $47.3 million for the quarter ended June 30, 2026, compared with $49.0 million a year earlier on a continuing-operations basis.
The company reported a GAAP net loss from continuing operations attributable to common stockholders of $7.9 million, or $0.16 per share. It also reported approximately 356,000 active subscribers, $25.1 million in cash, and no debt at quarter end.
Those are dated company-reported results. The earnings release predates the September investigation notice; the two disclosures do not, by themselves, establish a connection between the allegations and the company's financial performance.
Sources and scope
The investigation account above is attributed to Open Class Actions' LifeMD investigation notice. Financial information comes from LifeMD's updated Q2 2026 earnings release. Neither source establishes a financial outcome for the investigation.
Find related coverage and discussion on the LifeMD (LFMD) stock page.
Disclosure: TickerPosts and OpenClassActions.com share a founder. This article is informational reporting, not legal or investment advice.